Log in
Enquire now
‌

US Patent 7442777 Cytotoxicity mediation of cells evidencing surface expression of CD63

Patent 7442777 was granted and assigned to Arius Research on October, 2008 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Current Assignee
‌
Arius Research
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
74427770
Patent Inventor Names
Susan E. Hahn0
Luis A. G. da Cruz0
Paul Hinton0
Shankar Kumar0
Daad Sayegh0
David S. F. Young0
Helen P. Findlay0
Kristian Rogers0
Date of Patent
October 28, 2008
0
Patent Application Number
113624520
Date Filed
February 24, 2006
0
Patent Primary Examiner
‌
Misook Yu
0
Patent abstract

This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays which utilize the CDMAB of the instant invention.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 7442777 Cytotoxicity mediation of cells evidencing surface expression of CD63

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.